| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 154.47 | 25.8% |
| Total Income | 168.04 | 34.3% |
| Expenditure | 156.32 | 37.7% |
| PBT | 11.72 | 0.6% |
| Net Profit | 11.18 | 4.6% |
| OPM | 7.61% | 10.12pp |
| NPM | 6.65% | 5.31pp |
| EPS | 3.67 | 21.2% |
Bajaj Healthcare Achieves Significant Progress in Q4 & FY25 with Robust Growth Across Segments
27 May 2025 · 27 May 2025, 05:04 pm
Summary
Bajaj Healthcare Limited, one of the leading manufacturers of APIs, Intermediates and Formulations, announced its audited financial results for the quarter and year ended 31st March 2025. The company reported a 15.4% Y-o-Y growth in revenue from operations for Q4FY25, and a 14.6% Y-o-Y growth in revenue from operations for FY25. The gross margin expanded to 49% and EBITDA grew by 20% Y-o-Y.
Key Highlights
- 1
Acquired Genrx Pharmaceuticals Pvt. Ltd. to enhance in-house formulations manufacturing across allopathic, nutraceutical, and natural products
- 2
Secured CDMO contracts for 30 APIs with UK/EU partners and received 6 Certificates of Suitability (CEPs)
- 3
Centobamate has received a favorable SEC recommendation and is awaiting final approval from the DCGI
- 4
Magnesium L-Threonate (Magtein) is slated for launch next quarter
- 5
Successfully launched Pimavanserin in India through collaborations with few pharmaceutical companies
- 6
Appointed Mr. Rohan Parekh as Chief Financial Officer and KMP
Management Comments
Mr. Anil Jain
FY25 has been a transformational year for Bajaj Healthcare. We have delivered a strong financial turnaround and regained profitability, reflecting our commitment to operational discipline and long-term value creation. We closed the year with a net profit of 395 Mn, a significant swing from losses in the previous year. Gross margin expanded to 49%, supported by a more favorable product mix. EBITDA grew by 20% year-on-year, outpacing revenue growth and reflecting the benefits of improved operating leverage and cost efficiencies.
Informational and educational content only. Not investment advice.